Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07951346
PHASE2

N-Acetylcysteine as Adjuvant Therapy for Drug-Induced Hepatitis in Hospitalized Tuberculosis Patients

Sponsor: RSUP Persahabatan

View on ClinicalTrials.gov

Summary

Anti-tuberculosis drug-induced liver injury (AT-DILI) is a common side effect of tuberculosis (TB) treatment. It often forces TB drugs to be stopped temporarily, which may reduce treatment success. N-acetylcysteine (NAC) is an antioxidant that helps the body make glutathione and may help the liver recover. Most previous studies tested NAC to prevent liver injury rather than to treat liver injury that has already occurred. This study aimed to find out whether oral NAC, given as an adjuvant therapy, improves liver function and nausea-vomiting in hospitalized adults with drug-susceptible TB who developed AT-DILI. Participants were randomly assigned to receive effervescent NAC 600 mg twice daily for 7 days or no NAC. Liver tests (ALT, AST, and total bilirubin) were measured on days 0, 3, 6, and 9, and nausea and vomiting were assessed daily from day 0 to day 9.

Official title: Efficacy of N-Acetylcysteine as Adjuvant Therapy for Drug-Induced Hepatitis in Hospitalized Tuberculosis Patients at Persahabatan Hospital, Jakarta

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

28

Start Date

2026-02-01

Completion Date

2026-09-30

Last Updated

2026-11-20

Healthy Volunteers

No

Interventions

DRUG

N-acetylcysteine (NAC)

Effervescent N-acetylcysteine 600 mg tablet, taken orally twice daily (2 × 600 mg) for 7 days.

Locations (1)

Persahabatan National Respiratory Referral Hospital

Jakarta, DKI Jakarta, Indonesia